NPPA seeks clarification on license status from Clotrimazole mouth paint manufacturers
In relation to the fixation of ceiling price of antifungal drug clotrimazole 1% mouth paint, the National Pharmaceutical Pricing Authority (NPPA) panel has sought to get a clarification of approval of license status from the manufacturers and marketer of the drug.This came during the 38th meeting of 'Multidisciplinary Committee of Experts' meeting which was held on 24.01.2022 through...
In relation to the fixation of ceiling price of antifungal drug clotrimazole 1% mouth paint, the National Pharmaceutical Pricing Authority (NPPA) panel has sought to get a clarification of approval of license status from the manufacturers and marketer of the drug.
This came during the 38th meeting of 'Multidisciplinary Committee of Experts' meeting which was held on 24.01.2022 through video conference.
For more information, check out the full story on the link below:
NPPA seeks clarifications regarding ceiling price fixation of Clotrimazole mouth paint
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd